卵巢交界性肿瘤中p53和HER-2/neu的过表达

p53 and HER-2/neu overexpression in ovarian borderline tumors.

作者信息

Eltabbakh G H, Belinson J L, Kennedy A W, Biscotti C V, Casey G, Tubbs R R

机构信息

Department of Gynecology, Cleveland Clinic Foundation, Ohio 44195, USA.

出版信息

Gynecol Oncol. 1997 May;65(2):218-24. doi: 10.1006/gyno.1997.4661.

DOI:10.1006/gyno.1997.4661

PMID:9159328

Abstract

OBJECTIVE

To study p53 and HER-2/neu expression in borderline ovarian tumors (BLOT) by assessing their frequency, coexpression, and relationship to histologic type, FIGO stage, tumor recurrence, and survival.

METHODS

Forty-two patients with confirmed BLOT (25 serous, 13 mucinous, and 4 seromucinous) were followed for 1.5 to 14 years (mean, 6.3). Thirty (71%) patients had FIGO stage I and 12 (29%) had FIGO stage III disease. Paraffin-embedded sections from the 42 BLOT, 5 normal ovaries, and 10 benign ovarian cystadenomas were stained using monoclonal antibodies against human p53 (DAKO-p53, DAKO, Denmark) and HER-2/neu (C-erB-2, Triton, Parkway, CA). Positive staining was semiquantitated depending on the number of positively stained tumor cells. p53 and HER-2/neu overexpressions were correlated to each other, to histologic subtype, stage, tumor recurrence, and survival.

RESULTS

None of the patients had tumor recurrence. The 5- and 10-year disease-free survival was 100%. None of the normal ovaries or ovarian cystadenomas demonstrated overexpression of p53 or HER-2/neu. Ten (24%) BLOT demonstrated overexpression of p53 and 9 (21%) demonstrated overexpression of HER-2/neu. HER-2/neu overexpression was significantly greater in stage III than in stage I tumors (P = 0.0157). Seromucinous BLOT demonstrated significantly greater p53 overexpression compared with other histologic subtypes (P = 0.030). Coexpression of p53 and HER-2/neu occurred in 4 patients (9.5%). There was no significant correlation between the overexpression of p53 and HER-2/neu (P = 0.180) and no significant relationship between p53 and HER-2/neu overexpression and the presence of microinvasion, ability to perform optimal cytoreductive surgery, tumor recurrence, or survival.

CONCLUSIONS

p53 and HER-2/neu overexpression occurred in about 20-25% of BLOT overall and more commonly in seromucinous and advanced stage tumors. Coexpression occurred in 9.5% of the cases with no significant correlation between the expression of p53 and HER-2/neu.

摘要

目的

通过评估p53和HER-2/neu在卵巢交界性肿瘤（BLOT）中的表达频率、共表达情况及其与组织学类型、国际妇产科联盟（FIGO）分期、肿瘤复发和生存的关系，对其进行研究。

方法

42例确诊为BLOT的患者（25例浆液性、13例黏液性和4例浆液黏液性）接受了1.5至14年（平均6.3年）的随访。30例（71%）患者为FIGO I期，12例（29%）为FIGO III期疾病。对42例BLOT、5例正常卵巢和10例良性卵巢囊腺瘤的石蜡包埋切片，使用抗人p53（DAKO-p53，丹麦DAKO公司）和HER-2/neu（C-erB-2，美国加利福尼亚州帕克维尤市Triton公司）的单克隆抗体进行染色。根据阳性染色肿瘤细胞的数量进行半定量。p53和HER-2/neu的过表达相互关联，并与组织学亚型、分期、肿瘤复发和生存相关。

结果

所有患者均无肿瘤复发。5年和10年无病生存率均为100%。正常卵巢或卵巢囊腺瘤均未显示p53或HER-2/neu过表达。10例（24%）BLOT显示p53过表达，9例（21%）显示HER-2/neu过表达。HER-2/neu过表达在III期肿瘤中显著高于I期肿瘤（P = 0.0157）。与其他组织学亚型相比，浆液黏液性BLOT显示出显著更高的p53过表达（P = 0.030）。4例患者（9.5%）出现p53和HER-2/neu共表达。p53和HER-2/neu的过表达之间无显著相关性（P = 0.180），p53和HER-2/neu过表达与微浸润的存在、能否进行最佳细胞减灭术、肿瘤复发或生存之间也无显著关系。